Lung Cancer Therapeutics Market Size, Share, Opportunity, Analysis and Forecast 2017 - 2025
According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer death and the second most common cancer. The global lung cancer therapeutics market is expected to expand at a rapid pace during the forecast period due to the increase in incidence of lung cancer
According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer death and the second most common cancer. The global lung cancer therapeutics market is expected to expand at a rapid pace during the forecast period due to the increase in incidence of lung cancer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Lung</strong> <strong>Cancer</strong> <strong>Therapeutics</strong> <strong>Market</strong> - Global Industry <strong>Analysis</strong>,<br />
<strong>Size</strong>, <strong>Share</strong>, Growth, Trends, <strong>and</strong> <strong>Forecast</strong> <strong>2017</strong> – <strong>2025</strong><br />
Abnormal cell growth can lead to cancer. Cells that grow uncontrollably invade nearby tissues <strong>and</strong> further<br />
spread to other parts of the body through the lymphatic system. <strong>Lung</strong> cancer, also known as lung<br />
carcinoma, is characterized by uncontrolled cell growth in lungs. There are three major types of lung<br />
cancer: non-small cell lung cancer, small cell lung cancer, <strong>and</strong> lung carcinoid tumor. Non-small cell lung<br />
cancer is the common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers.<br />
Common symptoms of lung cancer include coughing, chest pains, weight loss, <strong>and</strong> shortness of breath.<br />
<strong>Lung</strong> cancer can be treated through various types of therapies such as chemotherapy, radiation therapy,<br />
vaccines, <strong>and</strong> immunotherapies.<br />
Request for brochure of this report -<br />
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5153<br />
According to Centers for Disease Control <strong>and</strong> Prevention (CDC), lung cancer is the primary cause of cancer<br />
death <strong>and</strong> the second most common cancer. The global lung cancer therapeutics market is expected to<br />
exp<strong>and</strong> at a rapid pace during the forecast period due to the increase in incidence of lung cancer. Cigarette<br />
smoking, pipes, cigar smoking, <strong>and</strong> constant exposure to asbestos are the key factors that can cause lung<br />
cancer. Prominent factors driving the global lung cancer therapeutics market include increase in geriatric<br />
population <strong>and</strong> rise in prevalence of unhealthy lifestyles. Availability of generic drugs, poor cancer<br />
diagnostic facilities in many countries, high cost <strong>and</strong> the adverse effect of radiation <strong>and</strong> chemotherapies<br />
are the factors likely to restrain the global lung cancer therapeutics market during the forecast period.<br />
The global lung cancer therapeutics market can be segmented based on chemotherapy, targeted therapy,<br />
radiotherapy, <strong>and</strong> geography. Based on chemotherapy, the global lung cancer therapeutics market can be<br />
categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine, <strong>and</strong> others. Chemotherapy is usually<br />
based on the combination of drugs. In terms of targeted therapy, the global lung cancer therapeutics<br />
market can be divided into Avastin, Tarceva, Iressa, Gilotrif, <strong>and</strong> others. Based on radiotherapy, the global<br />
lung cancer therapeutics market can be segregated into external beam radiotherapy, internal<br />
radiotherapy, <strong>and</strong> systemic radiotherapy.<br />
Geographically, the lung cancer therapeutics market can be segmented into North America, Europe, Asia<br />
Pacific, Middle East & Africa, <strong>and</strong> Latin America. North America is expected to dominate the global lung<br />
cancer therapeutics market in the near future, due to extensive technological advancements in the<br />
region.<br />
Europe is anticipated to be the second largest market for lung cancer therapeutics owing to the large<br />
government funding in the field of research <strong>and</strong> development of novel drugs <strong>and</strong> technological<br />
advancements in the fields of cancer. The global lung cancer therapeutics market in Asia Pacific is
estimated to exp<strong>and</strong> at a rapid pace the during the forecast period primarily owing to the development<br />
in healthcare facilities, rise in awareness about health, <strong>and</strong> increase in government funding. In terms of<br />
revenue, the lung cancer therapeutics market in China <strong>and</strong> India is likely to exp<strong>and</strong> significantly owing to<br />
the increase in population, development of economies, rise in prevalence of unhealthy lifestyle, <strong>and</strong> surge<br />
in air pollution.<br />
Key players operating in the global lung cancer therapeutics market are adopting various strategies such<br />
as acquisition <strong>and</strong> mergers, development of new <strong>and</strong> efficient drugs, geographical expansion, <strong>and</strong> strong<br />
research <strong>and</strong> development activities in order to maintain their position in the market. Prominent players<br />
operating in the global lung cancer therapeutics market include F. Hoffmann-La Roche Ltd., AstraZeneca<br />
plc, GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Pfizer, Inc., Agennix AG, <strong>and</strong> Eli Lilly <strong>and</strong> Company.<br />
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights,<br />
historical data, <strong>and</strong> verifiable projections about market size. The projections featured in the report have<br />
been derived using proven research methodologies <strong>and</strong> assumptions. By doing so, the research report<br />
serves as a repository of analysis <strong>and</strong> information for every facet of the market, including but not limited<br />
to: Regional markets, technology, types, <strong>and</strong> applications.<br />
Browse full report @ http://www.transparencymarketresearch.com/lung-cancer-therapeuticsmarkets.html<br />
The study is a source of reliable data on:<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<strong>Market</strong> segments <strong>and</strong> sub-segments<br />
<strong>Market</strong> trends <strong>and</strong> dynamics<br />
Supply <strong>and</strong> dem<strong>and</strong><br />
<strong>Market</strong> size<br />
Current trends/opportunities/challenges<br />
Competitive l<strong>and</strong>scape<br />
Technological breakthroughs<br />
Value chain <strong>and</strong> stakeholder analysis<br />
The regional analysis covers:<br />
North America (U.S. <strong>and</strong> Canada)<br />
Latin America (Mexico, Brazil, Peru, Chile, <strong>and</strong> others)<br />
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherl<strong>and</strong>s, <strong>and</strong><br />
Luxembourg)<br />
Eastern Europe (Pol<strong>and</strong> <strong>and</strong> Russia)<br />
Asia Pacific (China, India, Japan, ASEAN, Australia, <strong>and</strong> New Zeal<strong>and</strong>)<br />
Middle East <strong>and</strong> Africa (GCC, Southern Africa, <strong>and</strong> North Africa)<br />
The report has been compiled through extensive primary research (through interviews, surveys, <strong>and</strong><br />
observations of seasoned analysts) <strong>and</strong> secondary research (which entails reputable paid sources, trade<br />
journals, <strong>and</strong> industry body databases). The report also features a complete qualitative <strong>and</strong> quantitative
assessment by analyzing data gathered from industry analysts <strong>and</strong> market participants across key points<br />
in the industry’s value chain.<br />
A separate analysis of prevailing trends in the parent market, macro- <strong>and</strong> micro-economic indicators, <strong>and</strong><br />
regulations <strong>and</strong> m<strong>and</strong>ates is included under the purview of the study. By doing so, the report projects the<br />
attractiveness of each major segment over the forecast period.<br />
Highlights of the report:<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A complete backdrop analysis, which includes an assessment of the parent market<br />
Important changes in market dynamics<br />
<strong>Market</strong> segmentation up to the second or third level<br />
Historical, current, <strong>and</strong> projected size of the market from the st<strong>and</strong>point of both value <strong>and</strong> volume<br />
Reporting <strong>and</strong> evaluation of recent industry developments<br />
<strong>Market</strong> shares <strong>and</strong> strategies of key players<br />
Emerging niche segments <strong>and</strong> regional markets<br />
An objective assessment of the trajectory of the market<br />
Recommendations to companies for strengthening their foothold in the market<br />
Request for Discount of this report - @<br />
http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=5153<br />
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a market intelligence company, providing global business<br />
information reports <strong>and</strong> services. Our exclusive blend of quantitative forecasting <strong>and</strong> trends analysis<br />
provides forward-looking insight for thous<strong>and</strong>s of decision makers. TMR’s experienced team of analysts,<br />
researchers, <strong>and</strong> consultants, use proprietary data sources <strong>and</strong> various tools <strong>and</strong> techniques to gather,<br />
<strong>and</strong> analyze information. Our business offerings represent the latest <strong>and</strong> the most reliable information<br />
indispensable for businesses to sustain a competitive edge.<br />
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals,<br />
energy, food & beverages, semiconductors, med-devices, consumer goods <strong>and</strong> technology. These reports<br />
provide in-depth analysis <strong>and</strong> deep segmentation to possible micro levels. With wider scope <strong>and</strong> stratified<br />
research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research<br />
requirement.<br />
US Office Contact<br />
90 State Street, Suite 700<br />
Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
USA – Canada Toll Free: 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com
Change language